Please ensure Javascript is enabled for purposes of website accessibility
Search
Accessibility Menu
Concert Pharmaceuticals Stock Quote

Concert Pharmaceuticals (NASDAQ: CNCE)

Concert Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CNCE +201.08% -62.95% -17.99% -41%
S&P +32.06% +94.60% +14.23% +218%

Concert Pharmaceuticals Company Info

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.